跳至主要内容
临床试验/NCT03606629
NCT03606629已完成不适用

Solaris Endoprosthesis Performance in Treatment of Patients With Peripheral Occlusive Arterial Disease in the Iliac Territory - Post-Marketing Solaris I Study.

Scitech Produtos Medicos Ltda1 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2019年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
5
试验地点
1
主要终点
Major Adverse Events

研究概览

简要总结

Fifty patients will be treated with Solaris Endoprosthesis and followed up to 2 years with Walking Impairment Questionnaire and Doppler Ultrasound evaluation in 30 days, 6 months and 12 months.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Rutherford Class 2 to 5;
  • Tasc II Class A, B, C or D;
  • Unilateral or bilateral lesion, de novo or restenotic but not in-stent;
  • Target lesion of 3 to 10 cm length;
  • ≥ 50% stenosis or common iliac or external iliac artery;
  • Reference vessel diameter ≥ 5 and ≤ 9 mm;
  • Deep femoral artery patent and at least one infrapopliteal artery patent;
  • Informed Consent provided.

排除标准

  • Thrombocytopenia induced by heparina or tPA intravenous, clopidogrel, ticlopidine or aspirin sensitivity;
  • Target lesion near to aneurysm, highly calcified or excessively tortuous;
  • Previous stent on target vessel;
  • Presence of other lesions that need treatment within 30 days;
  • Rutherford Class 6;
  • Acute thrombotic occlusion;
  • History on amputation on the target limb.

结局指标

主要结局

Major Adverse Events

时间窗: 1 day

MAE is defined as death related to study device/ procedure, Myocardial Infarction, Target Vessel Revascularization or member amputation

Target Lesion Patency

时间窗: 6 months

Stenosis \< 50% and systolic velocity up to 2.5 cm2/s and no TLR

次要结局

未报告次要终点

研究者

发起方
Scitech Produtos Medicos Ltda
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验